Similar data were reported by a population-based cohort study carried out in Canada which aimed to assess the risk of urinary tract infections and recurrences associated with the initiation of SGLT2 inhibitors in comparison with DPP inhibitors, GLP1-RA, sulfonylureas, thiazolidinediones and insulin. This evidence concerns the gene INS and urinary tract infection.